Health ministry invites suggestions for renaming drug regulator CDSCO

New Delhi: The Union Health Ministry has invited suggestions for renaming the country’s drug regulator CDSCO in line with its expanded roles. In a public notice issued Thursday, the Central Drugs Standard Control Organisation (CDSCO) said its name was given keeping its role when it was created, but the present nomenclature was not reflecting its roles and responsibilities.

The notice said the role of CDSCO has expanded to several areas, including regulation of new drugs, vaccines and clinical trials, all imports pertaining to drugs, medical devices and cosmetics, Central Licensing Approval Authority for blood banks and vaccines, setting of standards under the Drugs and Cosmetics Act, 1940, among others.

It said R A Mashelkar in his report recommended creation of National Drug Authority (NDA) or Central Drug Authority (CDA).

The Drugs Technical Advisory Board (DTAB) in its 75th meeting held on January 3, 2017 had recommended renaming CDSCO as Indian Drugs Administration, the notice said, adding other name suggestions include Indian Medical Products Administration.

“In view of the above, it was decided to rename CDSCO and also have a new logo of its own. The new name should reflect the current role and encompass the areas administered by it.

“All the stakeholders are requested to send their suggestions/comments on the new name and the design,” the notice to various stakeholders, state drug controllers, pharma associations, said.

The ministry added that the suggestions should be submitted within two weeks from the date of the notice.

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies